Many studies have reported that MAP3K3 is highly correlated with the progression and treatment of nasopharyngeal carcinoma (Yin et al., 2019), ovarian cancer (Zhang Y. et al., 2019), lung cancer (He et al., 2015), and breast cancer (Fan et al., 2014). This evidence concerns the gene MAP3K3 and nasopharyngeal carcinoma.